Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“NovoSeven has been a lifesaving treatment for many people with Glanzmann Thrombasthenia, but I want those in the community to know that it’s important to remember that no medication is perfect.
Like all newer drugs, NovoSeven passed clinical trials, but long-term effects, rare complications, and real-world outcomes still take time to understand fully.
Approval does not mean a treatment is 100% effective or risk-free.
I hope that when adverse events or unexpected outcomes occur, Novo Nordisk thoroughly investigates them and shares those findings publicly. The GT community benefits from transparency, whether the results are positive or negative.
I always say:
Read the fine print, no matter how long or small; ask questions; and understand both the benefits and risks of any treatment you use.
The more we learn, the better care future GT patients will receive.”
Other posts featuring Peter Zdziarski on Hemostasis Today.
-
May 30, 2026, 18:10Open Registration for the 2026 Thrombosis Canada Annual Education Conference – Thrombosis Canada
-
May 30, 2026, 17:07Deepak Yadav: A Privilege to Talk on ESUS at CREST Stroke Conclave 2026
-
May 30, 2026, 16:59Syed A Rizvi: Medical Scoring Systems – Small Numbers, Big Clinical Decisions
-
May 30, 2026, 16:53Timothy “Tim” Sheehan: BNY Wealth Joins the Fight Against Blood Disorders In Support of Hemophilia of Georgia
-
May 30, 2026, 16:51Nouf Bahri: Anticoagulation Initiation for New-Onset Atrial Fibrillation in Critical Illness
-
May 30, 2026, 16:47Mohammed Al Rubaei: Where Do I Start When Evaluating a Patient With Suspected Hemolysis?
-
May 30, 2026, 16:39Psychological Impact of Hemophilia Gene Therapy – JTH
-
May 30, 2026, 16:37Ana Lucia Cabezas: Voluntary Blood Drives at Cardioinfantil Foundation Blood Bank
-
May 30, 2026, 16:08Anila Mathan: Assuming Leadership as HOD at Madras Medical Mission with the Inauguration of the MMM-APTUS-Tanker Laboratory